Surveillance imaging after autologous hematopoietic cell transplantation predicts survival in patients with diffuse large B cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma constituting approximately 30-40% of all non-Hodgkin lymphomas [1]. Conventional first-line chemotherapy for DLBCL yields a 5-year overall survival (OS) rate of 60-70% [1]. However, many patients either relapse (30-40%) or have initially refractory disease ( ∼10%) [2–5]. Those patients with disease sensitive to salvage chemotherapy may benefit from high-dose chemotherapy followed by autologous hematopoietic cell transplant (AHCT).

Source: Biology of Blood and Marrow Transplantation - October 23, 2019 Category: Hematology Authors: Malvi Savani, Mehmet Gencturk, Ryan Shanley, Zuzan Cayci, Christopher Wilke, Erica D. Warlick, Fiona He, Murali Janakiram, Daniel J. Weisdorf, Claudio G. Brunstein, Veronika Bachanova Source Type: research